🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPharmacology & MechanismsIncretin effect in healthy vs T2DM — May 2025 Page 2

Incretin effect in healthy vs T2DM — May 2025

CryptoCarl Tue, Mar 10, 2026 at 11:29 PM 6 replies 681 viewsPage 2 of 2
Dr.SleepRoch
Senior Member
1,123
5,678
Apr 2024
Rochester, MN
Mar 11, 2026 at 3:04 PM#6
Dr.KarenChen said:
Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction…

My labs after 3 months on glycaemic control: A1C 6.0%, fasting glucose 75 mg/dL, fasting insulin 8 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 6.5% and fasting glucose was 120 mg/dL. The improvement has been dramatic and consistent.

Last edited: Mar 11, 2026 at 7:04 PM
46 16sarah_TO, wendy_avl, jason_paloalto and 43 others
Reply Quote Save Share Report
TirzTom
Senior Member
2,789
9,876
Feb 2024
Florida
Online
Mar 11, 2026 at 9:14 PM#7
CryptoCarl said:
Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.

Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:

BiomarkerAssociationEvidence Level
Baseline BMIHigher BMI → greater absolute weight lossStrong
Fasting insulinHigher insulin → better responseModerate
GLP1R gene variantsrs6923761 → variable responsePreliminary
Baseline hsCRPHigher CRP → greater CV benefitModerate
Early weight loss (4 wk)≥3% at 4 wks → strong predictor of ≥10% at 68 wksStrong

The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.

Last edited: Mar 12, 2026 at 1:14 AM
45 15tom_AK, josh_phd_bmore, roxy_nash and 42 others
Reply Quote Save Share Report
lisa_labSD
Member
278
1,234
Oct 2024
San Diego, CA
Mar 12, 2026 at 3:24 AM#8
Dr.SleepRoch said:
My labs after 3 months on glycaemic control: A1C 6.0%, fasting glucose 75 mg/dL, fasting insulin 8 uIU/mL.

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)1191059183
Insulin (fasting)2513116
HOMA-IR5.53.51.91.3
Uric Acid8.26.95.85.0

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 5.5 to near 1.0 is a metabolic transformation.

44 14Dr.PulmRoch, maya_sedona, stefan_berlin and 41 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
EndoResFellow
Member
456
2,345
Sep 2024
Baltimore, MD
Mar 12, 2026 at 9:34 AM#9

A narrower follow-up, since the general answer is now clear:

How would you tell the difference between that and the alternative explanation?

43 13NurseKim_ATL, paul_denver, TinaHashiRN and 40 others
Reply Quote Save Share Report
CryptoCarl
Member
789
3,456
May 2024
Arizona
Mar 13, 2026 at 3:08 PM#10
lisa_labSD said:
Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone: Test Baseline Month 3 Month 6 Month 12…

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 5.2 (insulin resistant) → Current = 1.4 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

Last edited: Mar 13, 2026 at 7:08 PM
21 19ChrisMacros, KetoKyle, CanadaChris and 18 others
Reply Quote Save Share Report

Similar Threads

GLP-1R desensitization — β-arrestin-mediated internalization18 replies
Biased agonism at GLP-1R — Gs vs β-arrestin signaling balance13 replies
Semaglutide albumin binding and the C-18 fatty acid linker17 replies
GIP receptor pharmacology — why GIP agonism enhances GLP-113 replies
Glucagon receptor signaling — hepatic glycogenolysis and lipolysis16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register